Merck KGaA Acquires U.S. Proteomics Company ProteoPlex
Merck KGaA announced today that EMD Biosciences, Inc., its United States life sciences subsidiary located in San Diego, CA, has acquired ProteoPlex, Inc. of St. Louis, MO, privately owned research and development company specializing in functional genomics and proteomics. ProteoPlex will be a fully integrated part of EMD Biosciences. Both partners agreed not to disclose financial details of the transaction.
This acquisition provides Merck KGaA the opportunity to gain access to the emerging microarray market projected to approach USD 2 billion by the year 2008.
"The ProteoPlex brings a high level of sophisticated technology and personnel to Merck KGaA," said Dr. Bernd Reckman, Vice President and General Manager of Merck KGaA's Life Science Products Division. "Furthermore, the technology and competence of ProteoPlex are a perfect fit with our own proteomics R&D programs and will directly translate into new product offerings for our customers in the Life Sciences industry."
The ProteoPlex technology platform combines the power of parallel sample processing with the multiplex data generation capabilities of microarrays. "When you take the technology of ProteoPlex and the resources of Merck KGaA, you create a very powerful result," said David Smoller, Ph.D, President and CEO of ProteoPlex, Inc. "Moreover, the global sales and marketing leadership of Merck KGaA will provide accelerated access by customers to this important technology."
Most read news
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
ALTANA Accelerates Growth Momentum
Scale-invariant resistivity in cuprates
New International Marketing Manager at Spolchemie
FMC Corporation Increases Price of Hydrogen Peroxide
Ascenion coaches spin-off from the Helmholtz Zentrum München - eADMET to Improve Drug Discovery and Development Drugs

Light, flexible, efficient: Perovskite-based tandem solar cells - From the lab to the roof

WACKER Expands HCl Production for the Semiconductor Industry in Burghausen

Bodo Möller Chemie expands further into Eastern Europe - Bodo Möller Chemie opens own branch in Romania
Bruker AXS Announces Agreement to Acquire X-Ray Microanalysis Company Roentec AG
